This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Template:SubstanceBox/Gabapentin: Difference between revisions
Jump to navigation
Jump to search
>Kenan m Reverted edits by Aleksandar8239 (talk) to last revision by Tracer |
>Reddit-Drug-Advice The previous dosage ranges for gabapentin were extremely low compared to common use reported on Erowid and other forums, especially compared to the suggested ranges for pregabalin considering the medical equivalency evidence suggesting a 5:1 conversion ratio gaba:pregab (https://ahpnetwork.com/wp-content/uploads/2018/05/Admelog-May-2018.pdf , https://pubmed.ncbi.nlm.nih.gov/21692969/). Based on my experience and research I consider these new dose ranges much more realistic. |
||
| Line 56: | Line 56: | ||
|OralROA_Bioavailability=27% - 60%<ref>"Gabapentin dosing, indications, interactions, adverse effects, and more". | http://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011#showall</ref> | |OralROA_Bioavailability=27% - 60%<ref>"Gabapentin dosing, indications, interactions, adverse effects, and more". | http://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011#showall</ref> | ||
|OralROA_Threshold=[[Oral threshold dose::200]] [[Oral dose units::mg]] | |OralROA_Threshold=[[Oral threshold dose::200]] [[Oral dose units::mg]] | ||
|OralROA_Light=[[Oral min light dose::200]] - [[Oral max light dose:: | |OralROA_Light=[[Oral min light dose::200]] - [[Oral max light dose::900]] mg | ||
|OralROA_Common=[[Oral min common dose:: | |OralROA_Common=[[Oral min common dose::900]] - [[Oral max common dose::1500]] mg | ||
|OralROA_Strong=[[Oral min strong dose:: | |OralROA_Strong=[[Oral min strong dose::1500]] - [[Oral max strong dose::2400]] mg | ||
|OralROA_Heavy=[[Oral heavy dose:: | |OralROA_Heavy=[[Oral heavy dose::2400]] mg + | ||
|OralROA_TimelineFile= | |OralROA_TimelineFile= | ||
|OralROA_TimelineWidth= | |OralROA_TimelineWidth= | ||
Revision as of 20:20, 28 October 2021
| SubstanceBox/Gabapentin | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||
| Common names | Gabapentin, Neurontin, Gabarone, Gralise | ||||||||||||||||||||||||||
| Substitutive name | Gabapentin | ||||||||||||||||||||||||||
| Systematic name | 1-(Aminomethyl)cyclohexaneacetic acid | ||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||
| Psychoactive class | Depressant | ||||||||||||||||||||||||||
| Chemical class | Gabapentinoid | ||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
- ↑ "Gabapentin dosing, indications, interactions, adverse effects, and more". | http://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011#showall